A Study of Galcanezumab (LY2951742) in Participants With Episodic Migraine (PERSIST)

I5Q-MC-CGAX -

The reason for this study is to see if the drug galcanezumab is safe and effective inparticipants with episodic migraine.

Trial Summary

Age Range
18 - 65 years
Conditions the trial is for
Episodic Migraine
What the trial is testing?
Galcanezumab
Could I receive a Placebo?
Yes
Enrollment Goal
520
Trial Dates
Jul 30, 2019 - Mar 11, 2022
How long will I be in the trial?
The study will last about 53 weeks and may include up to 12 visits.
Trial Phase
III

Key Requirements

Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.

Participants Must:

  • Participants must have a diagnosis of migraine, with a history of migraine headaches of at least 1 year prior to screening and migraine onset prior to age 50

  • Participants must have a history of 4-14 migraine headache days and at least 2 migraine attacks per month on average within the past 3 months

Participants Must Not:

  • Participants must not be currently enrolled in any other clinical trial

  • Participants must not be taking or Have taken galcanezumab or another CGRP antibody

  • Participants must not be taking, or are expected to Take, therapeutic antibodies

  • Participants must not be allergic to multiple drugs or certain types of drugs sometimes used for headaches

  • Participants must not be pregnant or nursing

  • Participants must not have have a history of chronic migraine, daily persistent headache, cluster headache, medication overuse headache, migraine with brainstem aura, or hemiplegic migraine

Lilly Trial Alerts

Not the right fit? Sign up to receive updates about new trials that are listed or when a new trial site begins enrolling near you.